News archive search

Search the Newsreel

Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.

Showing
1–11
Matches
11
Sources here
8
Companies here
1
Search results Stored financial headlines

Active search

11 matching headlines

Ticker or company: SGMTMain company stories
Clear
Just inNext headlines
TipRanks Earnings Main company 🇺🇸 United States

Sagimet Highlights Q2 Results and Dermatology Focus Shift

Sagimet Biosciences (SGMT) reported its Q2 2026 results, announcing a strategic pivot towards dermatology. The company plans to advance its lead FASN inhibitor, denifanstat, into a U.S. Phase 3 acne trial and progress TVB-3567, backed by $257.6 million in cash which is expected to …

SGMT main company
Sharemaestro market context Trend signal active 52 weeks +48.4% SGMT stored weekly price path from 22 Aug 2025 to 14 Aug 2026
seekingalpha.com Earnings Main company 🇺🇸 United States

Sagimet Biosciences GAAP EPS of -$0.26 in-line

* Sagimet Biosciences press release [https://seekingalpha.com/pr/20614354-sagimet-biosciences-reports-second-quarter-2026-financial-results-and-provides-corporate] (SGMT [https://seekingalpha.com/symbol/SGMT]): Q2 GAAP EPS of -$0.26 in-line. * Cash, cash equivalents and marketable securities of $257.6 million as of June 30, 2026, expected to fund current operations through 2028, including through data readout of denifanstat Phase 3 …

SGMT main company
Sharemaestro market context Trend signal active 52 weeks +48.4% SGMT stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Search results

Matching headlines

External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.

globenewswire.com Analyst action Main company 🇺🇸 United States

Sagimet Biosciences to Participate in the Canaccord Genuity 46th Annual Growth Conference

FOSTER CITY, Calif., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced that management will participate in the Canaccord Genuity 46th Annual Growth Conference on Tuesday, August …

SGMT main company
Sharemaestro market context Trend signal active 52 weeks +48.4% SGMT stored weekly price path from 22 Aug 2025 to 14 Aug 2026
TradingView Market update Main company 🇺🇸 United States

Enterprise value to EBIT forward of Sagimet Biosciences Inc. Class A – DUS:0O2

This article provides financial data on Sagimet Biosciences Inc. Class A, specifically its enterprise value to EBIT forward. It lists the company on the Dusseldorf Stock Exchange under the ticker 0O2, indicating that the market is currently closed with no trades. The content appears …

SGMT main company
Sharemaestro market context Trend signal active 52 weeks +48.4% SGMT stored weekly price path from 22 Aug 2025 to 14 Aug 2026
TradingView Market update Main company 🇺🇸 United States

Enterprise value to EBIT forward of Sagimet Biosciences Inc. Class A – MUN:0O2

This article provides financial information for Sagimet Biosciences Inc. Class A (MUN:0O2), focusing on its enterprise value to EBIT forward. It indicates various financial tools and data available for the company on TradingView, along with general market and community information.

SGMT main company
Sharemaestro market context Trend signal active 52 weeks +48.4% SGMT stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Find financial news

Search the Newsreel

Use one field or combine several. Results are newest first.

Evidence context